Compass Pathways Plc (CMPS)
NASDAQ:CMPS
Want to see CMPS full AI Analyst Report?
CMPS Stock Chart & Stats
$6.66
-$0.42(-9.17%)
At close: 4:00 PM EST
$6.66
-$0.42(-9.17%)
Day’s Range― - ―
52-Week Range$2.25 - $14.76
Previous CloseN/A
Volume477.34K
Average Volume (3M)5.55M
Market Cap
$1.76B
Enterprise Value$791.70M
Total Cash (Recent Filing)$466.01M
Total Debt (Recent Filing)$2.83M
Price to Earnings (P/E)―
Beta1.61
Next Earnings
Jul 30, 2026EPS Estimate
-0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.15
Shares Outstanding134,949,330
10 Day Avg. Volume4,219,687
30 Day Avg. Volume5,546,616
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)-12.21
Price to Sales (P/S)0.00
P/FCF Ratio-4.10
Enterprise Value/Market Cap0.45
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-4.48
Forecast
1Y Price Target
$23.50Price Target Upside252.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-0.85
Revenue Forecast (FY)$2.50M
Bulls Say, Bears Say
Bulls Say
Robust Phase III DatasetA large, late‑stage clinical dataset with unprecedented 26‑week blinded follow‑up materially strengthens regulatory and payer confidence. Durable efficacy and tolerability signals across >1,000 patients improve approval probability, support labeling claims, and underpin long‑term commercial differentiation versus existing TRD options.
Rolling NDA + Priority VoucherA rolling submission plus a National Priority Voucher can structurally shorten FDA review once final data are filed, reducing calendar and regulatory execution risk. Faster review compresses time‑to‑market, helps secure first‑mover advantages, and limits protracted uncertainty that can erode commercial momentum and access planning.
Commercial Leadership & RunwayExperienced commercial hires and an expanding field team signal genuine launch preparedness, while disclosed cash runway into 2028 reduces near‑term financing pressure. Together these durable capabilities increase the odds of executing training, site activation and reimbursement strategies through initial commercialization phases.
Bears Say
Pre‑revenue, Heavy LossesPersistent pre‑revenue status and large, sustained operating losses create structural financing dependence and dilution risk. Reliance on external capital can constrain strategy, force timing compromises, and make execution contingent on fundraising windows, which is a lasting financial vulnerability until commercial revenue materializes.
Pending Pivotal 26‑week DataThe final 26‑week dataset is a structural gating item for completing the NDA; any delay or adverse signal would directly postpone submission and approval. This single pivotal dependency affects regulatory timing, labeling, and payer evidence packages, making it a durable execution risk until results are public and accepted by regulators.
Reimbursement & REMS UncertaintyCategory III CPT status, pending RUC valuation, undefined REMS requirements and expected payer prior‑authorization create structural reimbursement and access risk. Until billing codes, RVUs and REMS are finalized, per‑patient revenue, site economics and uptake remain uncertain, potentially limiting commercial penetration and margins.
COMPASS Pathways News
CMPS FAQ
What was Compass Pathways Plc’s price range in the past 12 months?
Compass Pathways Plc lowest stock price was $2.25 and its highest was $14.76 in the past 12 months.
What is Compass Pathways Plc’s market cap?
Compass Pathways Plc’s market cap is $1.76B.
When is Compass Pathways Plc’s upcoming earnings report date?
Compass Pathways Plc’s upcoming earnings report date is Jul 30, 2026 which is in 57 days.
How were Compass Pathways Plc’s earnings last quarter?
Compass Pathways Plc released its earnings results on May 13, 2026. The company reported $0.71 earnings per share for the quarter, beating the consensus estimate of -$0.439 by $1.149.
Is Compass Pathways Plc overvalued?
According to Wall Street analysts Compass Pathways Plc’s price is currently Undervalued.
Does Compass Pathways Plc pay dividends?
Compass Pathways Plc does not currently pay dividends.
What is Compass Pathways Plc’s EPS estimate?
Compass Pathways Plc’s EPS estimate is -0.39.
How many shares outstanding does Compass Pathways Plc have?
Compass Pathways Plc has 134,949,330 shares outstanding.
What happened to Compass Pathways Plc’s price movement after its last earnings report?
Compass Pathways Plc reported an EPS of $0.71 in its last earnings report, beating expectations of -$0.439. Following the earnings report the stock price went up 16.969%.
Which hedge fund is a major shareholder of Compass Pathways Plc?
Currently, no hedge funds are holding shares in CMPS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
COMPASS Pathways Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$23.50 (252.85% Upside)
$23.50 (252.85% Upside)
Blogger Sentiment
Neutral
CMPS Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 4.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.3%
Last 30 Days ▲ 15.1%
Last 30 Days ▲ 15.1%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
205.03%
12-Months-Change
Fundamentals
Return on Equity
-151.02%
Trailing 12-Months
Asset Growth
66.62%
Trailing 12-Months
Company Description
Compass Pathways Plc
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
CMPS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong clinical momentum (positive Phase III results, >1,000 patients in the program), concrete regulatory progress (rolling NDA alignment and a Commissioner's National Priority Voucher) and active commercial preparedness (experienced hires, CPT code groundwork, VA engagement and state-level rescheduling progress). These material positives are balanced against remaining execution and timing risks — notably pending 26-week data to complete the submission, CPT valuation and RUC/CMS steps, DEA/federal rescheduling sequencing, REMS and payer negotiation uncertainties, and competitive dynamics. Overall, the company presented multiple compelling strengths and a clear launch plan while acknowledging the remaining regulatory, reimbursement and operational work required before broad patient access.View all CMPS earnings summariesCMPS Stock 12 Month Forecast
Average Price Target
$23.50
▲(252.85% Upside)
Technical Analysis
Cross Country Healthcare
―
Oncology Institute
―
Talkspace
―
InnovAge Holding
―
Agilon Health
―
Ownership Overview
0.42% Insiders
1.28% Mutual Funds
52.49% Other Institutional Investors
42.31% Public Companies and Individual Investors